

Empowering precision oncology with one comprehensive test

Isabl integrates the whole genome and transcriptome to inform cancer care.

DISCOVER ISABL

SCROLL DOWN

THE OPPORTUNITY

Genetic profiling of tumor biopsies has revolutionized cancer care. However, many patients still don't benefit from existing panel-based diagnostic tests.



Isabl analyzes 100% of the tumor genome and transcriptome, revealing and identifying relevant cancer-associated mutations in every single sample.

We offer more comprehensive biomarker discovery – creating opportunities for better diagnosis for all patients.



Experts in the development and clinical implementation of innovative genomic technologies.

Our team brings together leaders in cancer genomics, molecular diagnostics, oncology, and biomarker development from top-tier institutions such as Memorial Sloan Kettering, Harvard, and Weill Cornell Medicine.

- OUR TEAM
- CAREERS





TECHNOLOGY

Making full genome testing a reality for all cancer patients.

Proud recipients of the FDA Breakthrough Device Designation, Isabl GxT technology is the most comprehensive genomic test in cancer with complete analysis of the entire tumor genome and transcriptome.

- OUR TECHNOLOGY

Our journey



Isabl Inc. spun off from Memorial Sloan Kettering Cancer Center in 2020 and has been funded by Two Sigma Ventures, Y Combinator, BoxOne Ventures, and others.

Latest news and Publications

NEWS

Isabl featured in TechCrunch

19 Dec, 2023

PUBLICATIONS

Whole Genome Landscape of Male Breast Cancer

19 Dec, 2023

PUBLICATIONS

Whole Genome and Transcriptome Sequencing Analyses Elucidate Relevant Molecular Phenotypes in Gastric/Gastroesophageal Junction (GEJ) Adenocarcinomas

19 Dec, 2023

PUBLICATIONS

Identification of Genetically Relevant Clonal Signature Targets in Malignant Genomes and Transcriptomes

19 Dec, 2023

[VIEW MORE →](#)



The future of cancer genomics, today.

[JOIN US](#)

[CONTACT US](#)



[Technology](#) [Company](#) [Careers](#) [Resources](#) [Contact](#)

© Isabl 2024 · [Privacy Policy](#) · [FCOI Policy](#) · Made by ++



COMPANY

A team of experts, radically transforming cancer diagnosis.



Meet Our Amazing Team

Targeted sequencing – a significant step in tailored cancer care. But, only a select population have benefited from these advancements.

Isabl technology unlocks the full potential of genomic medicine – contributing to the advancement of research aiming to provide better outcomes for every patient.




WHERE WE COME FROM

Proven feasibility — backed by clinically relevant timeframes.

Our team has developed the technology to profile tumor biopsies with whole genome and transcriptome sequencing in clinically relevant timeframes.

We have demonstrated the clinical feasibility of our test. Witnessing the impact of this technology on clinical care has been a transformative experience. We feel the urgency to make Isabl GxT available to every cancer patient.





Leveraging the excellent work of those who came before us.

The pioneering advancements of the team at Isabl continue bring us closer to our goals.



INCREASE CLARITY + REDUCE COMPLEXITY

Deliver clinically relevant findings to physicians and directs biopharma resources into cDX development – with more clarity, not greater complexity.



UNCOVER ALL TREATMENT OPTIONS

Provide truly comprehensive diagnosis and customized cancer treatment options with the potential to improve the outcomes for cancer patients around the world.



GUARANTEE RAPID RESULTS

Enable rapid cancer whole genome and transcriptome test (cWGTS) in clinical timeframes.







OUR MISSION

To unlock the mystery of the whole cancer genome – and radically improve diagnosis and treatment for all patients, everywhere.

OUR GOALS ARE TO

- ✔ Leverage the power of the entire human genome to radically transform cancer diagnosis and treatment.
- ✔ Drive evidence-based molecular biomarker discoveries
- ✔ Transform breakthrough hypotheses and discoveries into useful, state-of-the-art diagnostic tests
- ✔ Develop patient-tailored, clinical decision support tools
- ✔ Lead world-class scientific programs with clinical impact
- ✔ Make a remarkable difference – one patient at a time

Our core values

 <p>FOCUS Dedicated to Deep Insights in Oncology</p>	 <p>NIMBLE Adaptable Expertise in Diagnostics</p>	 <p>INNOVATION Pioneering Tomorrow's Diagnostic Solutions</p>
 <p>RELIABILITY Consistent Accuracy, Trusted Results</p>	 <p>TENACITY Unyielding Commitment to Discovery and Care</p>	 <p>INTEGRITY Ethical Excellence in Every Step</p>

TEAM

Isabl is the product of leading, world-class minds.

Over 120 years combined experience in medical diagnostics and cancer research across dozens of top cancer facilities, schools, and research and treatment centers.

Leadership team



Eli Dancammanil



Ivan Medina



Andrew Kung

Em Papachristianou

PHD, CEO AND SCIENTIFIC CO-FOUNDER

Expertise in the application of AI to precision medicine. Publications in NEJM, Nature Genetics, Nature Medicine, >43K citations (h-index 70).



Juan Medina

CTO AND TECHNICAL CO-FOUNDER

Biomedical and Software Engineer. Lead developer of the Isabl Platform.



Andrew Kung

MD PHD, MEDICAL CO-FOUNDER

Chair, Department of Pediatrics Memorial Sloan Kettering. Early adopter and KOL of precision genomic medicine approaches in clinical oncology (h-index 112).



Isabl Team



Minal Patel

Director of Operations



Stan Skrypzak

Chief Business Officer (acting)



Max Levine

Computational Biology Engineer



Kevin Hadi

Computational Biologist



Aditya Deshpande

Computational Biologist



Gunes Gundem

Computational biology consultant



Scientific Advisory Board






Matthew Meyerson (Chairman)

Professor of Pathology and Genetics at Harvard Medical School, and Director for Cancer Genome Discovery at DFCI (h-index ~220). Co-founder of Foundation Medicine.



Our journey



Isabl Inc. spun off from Memorial Sloan Kettering Cancer Center in 2020 and has been funded by Two Sigma Ventures, Y Combinator, BoxOne Ventures, and others.

The future of cancer genomics, today.

[JOIN US](#)[CONTACT US](#)

TECHNOLOGY

Unprecedented clarity into tumor biology with 100% cancer genome and transcriptome analysis.

Current tests detect only a few frequently mutated genes. Leaving many patients – especially those with less common cancers – without clinically relevant findings and limited treatment options.

The proprietary Isabl GxT platform detects all cancer-associated mutations, reporting the subset of clinically-relevant biomarkers, and revealing new opportunities for precision diagnostics, disease surveillance, and biomarker discovery – for every cancer patient.

A sample is taken from the patient



THE OPPORTUNITY

Current approaches to sequencing have only been able to provide insight to 1% of the full genome – until now.



ONE COMPREHENSIVE TEST

From biopsy to an actionable report in clinically relevant timeframes, Isabl integrates data from 100% of the cancer DNA, germline DNA, and the transcriptome into a single diagnostic workflow. No more diagnostic odysseys.



NOVEL BIOMARKER DISCOVERY

Comprehensive characterization of the genomic landscape across mutation classes removes any blind spots for biomarker development and identification of responder or non-responder subgroups.




NOT JUST MORE DATA, BETTER DATA

Isabl identifies all cancer associated mutations including mutations that no other cancer diagnostic assay can detect today, improving diagnosis for many patients.

The Isabl Difference

It's not just about having more data – it's about having the right data, delivered in the right format. Isabl looks at the whole picture – and delivers it in a clear and concise report to give you the information you need to provide truly personalized care to your patients.




	Isabl GxT		Standard of care			
	Genome	RNA Seq	Targeted RNA	Targeted DNA	Exome	
HRD	☑			☑	☑	Other biomarkers
Mutational Burden	☑			☑	☑	
MSI	☑			☑	☑	
Immunophenotypes	☑	☑				Expression & Immunoprofiling
Neo-antigens	☑	☑	☑		☑	
Gene expression		☑				DNA small mutations
Non-coding mutations	☑					
Rare cancer genes	☑				☑	
Common cancer genes	☑			☑	☑	
Rearrangements	☑					Structural changes
Fusion genes	☑	☑	☑			
Copy number	☑			☑	☑	

☑ Complete ☑ Partial

How our process works

Cancer diagnoses and prognoses are complex – but they don't have to be complicated. Isabl simplifies the process significantly, while providing incomparably clear, compelling results.




Informed research, evidence-led standards, better patient experience.

Isabl is collaborating with oncologists and cancer centers to evaluate clinical validity and utility across solid and heme cancer indications. Isabl GxT will be available for RUO release in Q2 2024. Now, we're looking for more partners to help continue our learning.

- One comprehensive test from a single biopsy
- End diagnostic odysseys
- Data driven treatment planning
- Improved diagnosis
- Better risk stratification
- Improved treatment planning
- Informed eligibility for clinical trials

CONTACT US



Decoding Cancer: Uncover Hidden Biomarkers, Enhance Drug Response.

Rare cancers, rare variants – Isabl's FDA designated Breakthrough technology can help find patients with untapped biomarkers that might predict response.

- Gain accurate mutation detection including gene mutations, allelic imbalances, structural variants, fusion genes, mutation signatures, TMB, MSI, HRD, and gene expression
- Comprehensive assessment of clinical trial eligibility
- Understand why some patients respond to a drug and why others don't

CONTACT US

ISABL PRODUCTS

The most comprehensive WGS-based diagnostics.

With our strong scientific foundation and deep technical expertise, Isabl is at the forefront of WGS analysis. Our suite of products will set the course of future cancer care.



Isabl GxT Solid for solid tumors

Cancer whole genome and transcriptome and germline whole genome. Applied to Fresh Frozen (FF) and Formalin-fixed Paraffin Embedded (FFPE) samples with matched blood.



Isabl GxT Heme for hematological cancers

Cancer whole genome and transcriptome (no germline sample required). From blood and bone marrow (BM).

ISABL'S CORE

We are a data-driven company working with advanced analytics.

With a strong scientific foundation, deep technical expertise, and using machine learning/AI to develop next generation biomarkers from WGS data, Isabl is creating one of the largest WGS datasets in the world that captures every relevant genetic biomarker now and in the future.

That means access to best-in-class genomic expertise.

OUR COMPANY



Clinical cancer genomics has made great strides using targeted panels, but we are still missing what happens in 99% of the genome. Moving to whole genome and whole transcriptome sequencing will allow us to find all the key alterations

in cancer genomes and help us identify more opportunities for patient tailored therapy.”



- Dr. Matthew Meyerson, MD, PhD

The future of cancer genomics, today.

[JOIN US](#)

[CONTACT US](#)



[Technology](#) [Company](#) [Careers](#) [Resources](#) [Contact](#)


© Isabl 2024 · [Privacy Policy](#) · [FCOI Policy](#) · Made by ++



CAREERS

An extraordinary challenge and rewarding mission – to the final frontier of genomic medicine.

[→ Check Out Current Openings](#)



WORKING AT ISABL

Our mission is nothing short of extraordinary – just like you.

We're looking for exceptional individuals ready to take on a formidable challenge. Help us build the diagnostic tool we need – and that cancer patients deserve.

Remote by default. Equity for all. Top benefits.

Remote first – but with an incredible space you just might want to visit anyway. Our NYC office

is ideally suited to when you need some dedicated space to think. Amazing views. Inspiring collaboration – and unlimited coffee to help fuel those conversations and experiments.



The name “Isabl” represents a shared mission.

We come from varied origins and backgrounds, speak with accents, and hold different political views and religious beliefs. Yet – we come together to fight a disease that affects us all.

Isabl is named for a loved one who lost her fight, serving as a reminder of the mission at hand.

We are all in this for Isabl. We are all in this together.

OUR CULTURE AND VALUES

With knowledge comes power.

And with power comes opportunity – the opportunity to provide a new 360° scope of insight into patient health, cancer diagnostics, and highly personalized treatment plans. **This is what Isabl stands for.**

OUR COMPANY



Solve the mysteries of the cancer genome with big data from the most advanced diagnostics in the world



Enable fully customized treatment plans to radically improve cancer outcomes

JOB POSITIONS

Help us create the tool we all need – and that cancer patients deserve.

SEE OPEN POSITIONS



Want to join our mission, but can't find the position for you?

We want to meet you. Tell us how you can help at:
careers@isabl.com

The future of cancer genomics, today.


JOIN US

CONTACT US



Technology Company Careers Resources Contact

© Isabl 2024 · Privacy Policy · FCOI Policy Made by ++



LATEST PUBLICATION

Isabl featured in TechCrunch

READ MORE



All ²⁴ News ⁴ Publications ²⁰ Case Studies ⁰ Search

NEWS 19 Dec, 2023

Isabl featured in TechCrunch



NEWS 20 Dec, 2023

Matthew Meyerson joins Isabl as Chairman of the Scientific Advisory Board



NEWS 20 Dec, 2023

MSK Starts Offering Pediatric Cancer Patients Whole-Genome, Transcriptome Sequencing

Pre-spinout article on Isabl Analytics at MSKCC for pediatrics.



NEWS 20 Dec, 2023

New Type of Genetic Testing Aims To Benefit Children and Young Adults With Cancer

Pre-spinout MSKCC new article on Isabl Analysis.



The future of cancer genomics, today.

JOIN US

CONTACT US



[Technology](#) [Company](#) [Careers](#) [Resources](#) [Contact](#)

© Isabl 2024 · [Privacy Policy](#) · [FCOI Policy](#) · Made by ++

